Bionic Vision Technologies 04.13.17
Retinal implant developer Bionic Vision Technologies (BVT) has raised $18 million from Hong Kong-based China Huarong International Holdings Ltd. and State Path Capital Limited to develop and commercialize its next-generation devices aimed at restoring vision to the blind.
This financing formally launches the company as it transitions to a commercialization stage business. To date, the development of Australia’s ‘bionic eye’ has been funded through a five-year $50 million Special Research Initiative grant administered by the Australian Research Council.
“Our investment in BVT aligns with our strategy of backing transformative new technology with significant global potential,” said Alastair Lam, a nephew of Hong Kong-based business magnate, investor and philanthropist Sir Li Ka-shing. He is the chairman of State Path Capital Limited. “Given BVT's commitment to developing and delivering a revolutionary solution for vision loss, we believe its ‘bionic eye’ technology has the potential to transform the lives of millions of people and meet a large unmet need. Our investment support will help move the current product closer to market and the communities who will benefit."
BVA consortium members, whose organizations become alongside the new investors, comprise of the University of Melbourne, the University of New South Wales, the Bionics Institute, Centre for Eye Research Australia, CSIRO’s Data 61, The Royal Victorian Eye & Ear Hospital, Western Sydney University, and the Australian College of Optometry. BVT will use the new funds to manufacture devices and begin a human clinical trial of its "bionic eye" implant in patients with the inherited degenerative eye condition called retinitis pigmentosa. The condition is the most common cause of inherited blindness and affects more than 1.5 million people worldwide.
The investment was made on the basis of BVT’s advanced work in developing bionic vision technologies including a successful clinical trial of a prototype device in three patients. BVT’s bionic eye has a number of significant advantages over competitors, including a superior surgical approach, stability of the device, and unique vision processing software that potentially improves the patient’s experience.
“This investment is an important milestone for our technology and an endorsement of our approach to making a positive impact on global health. These new funds will help create an innovative, solution to potentially help improve the lives of blind people,” Bionic Vision Technologies Executive Chairman Robert Klupacs said. “The funding will propel this technology into clinical trials in coming months as we work towards securing regulatory approval and a commercial launch in key markets where loss of vision is a significant medical burden. There is currently no treatment for conditions such as retinitis pigmentosa and our new investors recognise BVT has developed a world-leading solution with potential to make a significant impact patient’s sight and lifestyle.”
The U.S. National Eye Institute estimates that 1 in 4,000 people have retinitis pigmentosa worldwide with a higher number of cases in China and India compared to other countries in the developed world.
The development of a retinal implant will draw on BVT’s expertise and track record of success in this field.
The implant BVT has created is placed at the back of the eye where it stimulates the surviving nerve cells in the retina with electrical signals created from images collected by an externally worn camera. Next-stage clinical trials are scheduled to start in coming months in Melbourne, Australia.
Based on the results of the initial trial in 2012-2014, further patients will be recruited and monitored for up to two years. Patients will be surgically implanted with a permanent device to wear in their everyday activities. Early trials of the device only monitored patients in the clinic. Researchers will measure mobility and independence.
The BVT product pipeline consists of two generations of devices which aim to increase mobility and independence of patients and give increasing visual acuity.
The devices operate by electrically stimulating the remaining retinal cells in patients with retinal degeneration. BVT has distinct and unique advantages over its competitors which it believes will lead to much safer and more effective prostheses. In particular, the novel surgical procedure which uses a natural pocket called the suprachoroidal space is expected to be far superior to surgical methods currently used. World leading vision processing technology also allows BVT to be constantly upgrading the patients’ experience without the need for further surgery.
Bionic Vision Technologies is a privately held Australian company developing visual prostheses to restore vision to the blind. The company aims to be the world leader in the development and production of suprachoroidal positioned retinal prostheses for restoring vision to the blind and the potential to slow the progression of retinal degeneration. BVT products are based on intellectual property generated by Bionic Vision Australia; a national consortium that was supported by the Australian Research Council through its Special Research Initiative in Bionic Vision Science and Technology. BVT’s shareholders include State Path Capital Limited, BVI, UOM Commercial Ltd., NewSouth Innovations, Bionics Institute, Centre for Eye Research Australia, NICTA IPR, The Royal Victorian Eye & Ear Hospital, Western Sydney University, and the Australian College of Optometry.
BVT was advised by David Wells of Falcon Corporate Advisory.
This financing formally launches the company as it transitions to a commercialization stage business. To date, the development of Australia’s ‘bionic eye’ has been funded through a five-year $50 million Special Research Initiative grant administered by the Australian Research Council.
“Our investment in BVT aligns with our strategy of backing transformative new technology with significant global potential,” said Alastair Lam, a nephew of Hong Kong-based business magnate, investor and philanthropist Sir Li Ka-shing. He is the chairman of State Path Capital Limited. “Given BVT's commitment to developing and delivering a revolutionary solution for vision loss, we believe its ‘bionic eye’ technology has the potential to transform the lives of millions of people and meet a large unmet need. Our investment support will help move the current product closer to market and the communities who will benefit."
BVA consortium members, whose organizations become alongside the new investors, comprise of the University of Melbourne, the University of New South Wales, the Bionics Institute, Centre for Eye Research Australia, CSIRO’s Data 61, The Royal Victorian Eye & Ear Hospital, Western Sydney University, and the Australian College of Optometry. BVT will use the new funds to manufacture devices and begin a human clinical trial of its "bionic eye" implant in patients with the inherited degenerative eye condition called retinitis pigmentosa. The condition is the most common cause of inherited blindness and affects more than 1.5 million people worldwide.
The investment was made on the basis of BVT’s advanced work in developing bionic vision technologies including a successful clinical trial of a prototype device in three patients. BVT’s bionic eye has a number of significant advantages over competitors, including a superior surgical approach, stability of the device, and unique vision processing software that potentially improves the patient’s experience.
“This investment is an important milestone for our technology and an endorsement of our approach to making a positive impact on global health. These new funds will help create an innovative, solution to potentially help improve the lives of blind people,” Bionic Vision Technologies Executive Chairman Robert Klupacs said. “The funding will propel this technology into clinical trials in coming months as we work towards securing regulatory approval and a commercial launch in key markets where loss of vision is a significant medical burden. There is currently no treatment for conditions such as retinitis pigmentosa and our new investors recognise BVT has developed a world-leading solution with potential to make a significant impact patient’s sight and lifestyle.”
The U.S. National Eye Institute estimates that 1 in 4,000 people have retinitis pigmentosa worldwide with a higher number of cases in China and India compared to other countries in the developed world.
The development of a retinal implant will draw on BVT’s expertise and track record of success in this field.
The implant BVT has created is placed at the back of the eye where it stimulates the surviving nerve cells in the retina with electrical signals created from images collected by an externally worn camera. Next-stage clinical trials are scheduled to start in coming months in Melbourne, Australia.
Based on the results of the initial trial in 2012-2014, further patients will be recruited and monitored for up to two years. Patients will be surgically implanted with a permanent device to wear in their everyday activities. Early trials of the device only monitored patients in the clinic. Researchers will measure mobility and independence.
The BVT product pipeline consists of two generations of devices which aim to increase mobility and independence of patients and give increasing visual acuity.
The devices operate by electrically stimulating the remaining retinal cells in patients with retinal degeneration. BVT has distinct and unique advantages over its competitors which it believes will lead to much safer and more effective prostheses. In particular, the novel surgical procedure which uses a natural pocket called the suprachoroidal space is expected to be far superior to surgical methods currently used. World leading vision processing technology also allows BVT to be constantly upgrading the patients’ experience without the need for further surgery.
Bionic Vision Technologies is a privately held Australian company developing visual prostheses to restore vision to the blind. The company aims to be the world leader in the development and production of suprachoroidal positioned retinal prostheses for restoring vision to the blind and the potential to slow the progression of retinal degeneration. BVT products are based on intellectual property generated by Bionic Vision Australia; a national consortium that was supported by the Australian Research Council through its Special Research Initiative in Bionic Vision Science and Technology. BVT’s shareholders include State Path Capital Limited, BVI, UOM Commercial Ltd., NewSouth Innovations, Bionics Institute, Centre for Eye Research Australia, NICTA IPR, The Royal Victorian Eye & Ear Hospital, Western Sydney University, and the Australian College of Optometry.
BVT was advised by David Wells of Falcon Corporate Advisory.
